

<b>Reference:</b>	FOI.20352.26
<b>Subject:</b>	Treatment of inflammatory diseases
<b>Date of Request:</b>	5 May 2026

### Your request and our response

How many patients were treated with the following drugs from the following departments (for any disease) from the start of October 2025 to the end of December 2025?

*Please use the latest available 3 months if October to December is not available and specify which 3 months have been used.*

Hywel Dda University Health Board (UHB) provides within the table overleaf, the number of Dermatology and Rheumatology patients treated with the listed medications for any disease, during the period 1 January to 31 March 2026.

Where the figures in the table have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

<b>Drug Name</b>	<b>Dermatology</b>	<b>Rheumatology</b>
Adalimumab	97	362
Apremilast	10	26
Bimekizumab	*	*
Brodalumab	*	0
Certolizumab Pegol	0	37
Deucravacitinib	0	0
Etanercept	*	165
Etrasimod	0	0
Filgotinib	0	21
Golimumab	0	25
Guselkumab	*	0
Infliximab (Biosimilars)	0	19
Infliximab (Remicade)	0	0
Ixekizumab	0	5
Mirikizumab	0	0
Ozanimod	0	0
Risankizumab	37	*

Secukinumab	41	64
Tildrakizumab	*	0
Tofacitinib	0	7
Upadacitinib	8	29
Ustekinumab	29	16
Vedolizumab	0	*